Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026)

Neurocrine Biosciences has reported Current Assets for 17 years, with the latest figure at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 48.73% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (up 48.73% YoY), and the FY2025 full-year result was $2.5 billion, up 46.27% from the prior year.
• Current Assets for Q1 2026 stood at $2.4 billion, down from $2.5 billion in the prior quarter.
• The five-year high for Current Assets was $2.5 billion in Q4 2025, with the low at $1.0 billion in Q1 2022.
• Historically, Current Assets has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2023.
• Annual changes were most pronounced in 2022 — Current Assets jumped 49.41% — and 2025, when it dropped 8.95%.
• Neurocrine Biosciences' Current Assets stood at $1.5 billion in 2022, then grew by 10.56% to $1.6 billion in 2023, then advanced by 7.32% to $1.7 billion in 2024, then surged by 46.27% to $2.5 billion in 2025, then dropped by 3.43% to $2.4 billion in 2026.
• The last three Current Assets figures came in at $2.4 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.